Firefly Neuroscience, Inc. filings document the public-company disclosures of an AI precision-neuroscience business focused on EEG/ERP brain analytics and related software platforms. Its Form 8-K reports cover material financing agreements, including securities purchase agreements for unit issuances and at-the-market common stock sales arrangements, along with corporate events affecting its capital structure.
Proxy and annual meeting filings describe Firefly Neuroscience governance matters, including director elections, auditor ratification, incentive plan amendments, common stock voting mechanics and stockholder vote results. The filing record also provides formal disclosure context for the company’s operating model, commercialization activities, equity plan administration and governance obligations as a Nasdaq-listed Delaware corporation.
Firefly Neuroscience, Inc. (AIFF) granted director Stella Vnook 84,033 deferred stock units on September 25, 2026, under its 2024 Long-Term Incentive Plan. The units vest quarterly over 12 months, and each represents a contingent right to receive one common share. Her reported deferred stock unit position following the grant was 149,962 units.
Firefly Neuroscience, Inc. director Brian M. Posner received 84,033 deferred stock units on September 25, 2026, under the company's 2024 Long-Term Incentive Plan. The units vest quarterly over a twelve-month period, and each represents a contingent right to receive one share of common stock. Posner's reported direct position following the grant was 149,962 deferred stock units.
Firefly Neuroscience, Inc. (AIFF) director Arun Swarup Menawat was granted 126,050 deferred stock units on September 25, 2026, under the company’s 2024 Long-Term Incentive Plan. The units vest quarterly over twelve months, and each represents a contingent right to receive one common share. His reported position after the grant was 216,609 deferred stock units.
FIREFLY NEUROSCIENCE, INC. (AIFF) reported the initial equity holdings of Chief Accounting Officer Jessica Lucia Paz. She holds a stock option to buy 50,000 shares of common stock at an exercise price of $1.11 per share, expiring on September 8, 2036. The option vests as to 12,500 shares on September 8, 2027, with the remaining 37,500 shares vesting in 12 equal quarterly installments of 3,125 shares each, ending on August 15, 2030.
Firefly Neuroscience, Inc. (AIFF) reported that its board of directors terminated Chief Financial Officer Paul Krzywicki, effective September 24, 2026, stating that the termination was not due to any disagreement regarding operations, policies, or practices. On September 8, 2026, the board appointed Jessica Paz as Chief Accounting Officer and approved her employment terms.
Under her offer of employment, Ms. Paz will receive an annual base salary of $215,000 and a stock option to purchase 50,000 shares of common stock at the fair market value on the grant date, vesting over four years, subject to continued employment. She entered into the company’s standard indemnification and confidentiality/non-compete/non-solicitation agreements and will be covered under any directors’ and officers’ liability insurance on the same basis as other senior officers.
Firefly Neuroscience, Inc. reported continued operating losses for the quarter and six months ended June 30, 2026 while significantly expanding its balance sheet through equity financings. Revenue reached $514 thousand for the quarter and $999 thousand for the first half of 2026, up sharply from 2025 levels, largely driven by the Evoke Neuroscience acquisition and subscription-based deployments of its FDA-cleared Evoke EEG System across more than 85 U.S. sites.
Total assets rose to $16.8 million, with cash and cash equivalents increasing to $9.2 million from $2.7 million at year-end 2025, primarily due to March–April 2026 private placements that generated about $10.3 million in net proceeds. Shareholders’ equity improved to $14.7 million, although the company still carried an accumulated deficit of $115.6 million and an operating cash outflow of $3.7 million in the first half.
Management explicitly states that recurring losses, negative operating cash flows, and insufficient revenue raise substantial doubt about the ability to continue as a going concern within one year. An at-the-market facility of up to $7.4 million remains unused, and 14.6 million warrants plus equity awards represent significant potential dilution. Management also concludes that disclosure controls and internal control over financial reporting were not effective as of June 30, 2026 due to material weaknesses, with remediation efforts ongoing.
Firefly Neuroscience, Inc. held its 2026 annual meeting on August 5, 2026, where stockholders approved Amendment No. 2 to the 2024 Long-Term Incentive Plan, increasing the Plan Share Limit by 2,000,000 shares of common stock and updating the plan’s evergreen provision. Stockholders also elected Arun Menawat as a Class III director to serve until 2029 and approved, on a non-binding advisory basis, compensation for named executive officers.
Stockholders approved a charter amendment decreasing total authorized capital from 5,001,000,000 shares to 101,000,000, consisting of 100,000,000 shares of common stock and 1,000,000 shares of preferred stock, effective August 5, 2026. They ratified CBIZ Canada, LLP as independent auditor and approved an adjournment proposal. Shares outstanding on the June 8, 2026 record date were 15,604,571, with 9,703,536 shares represented, constituting a quorum.
Firefly Neuroscience, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on August 5, 2026 at 10 a.m. Eastern Time. Stockholders of record as of June 8, 2026, when 15,604,571 common shares were outstanding, are entitled to vote.
Proposals include electing Class III directors, ratifying CBIZ Canada, LLP as independent auditor for 2026, an advisory say-on-pay vote on named executive officer compensation, and approving Amendment No. 2 to the 2024 Long-Term Incentive Plan. Stockholders are also asked to approve a Certificate of Amendment to decrease the total number of authorized shares and to approve a potential adjournment of the meeting if more time is needed to solicit proxies.
The proxy details Board composition, independence, and committee structures, and discloses 2025 compensation, including $1,063,718 for CEO Greg Lipschitz and $748,335 for President and COO David DeCaprio. Directors and executive officers as a group beneficially own 6.90% of outstanding common stock.
Firefly Neuroscience, Inc. filed a resale registration covering up to 20,499,999 shares of its common stock for resale by identified selling stockholders.
The company states it is not selling any shares hereunder and will not receive proceeds from resales; it may receive proceeds only if the March 2026 Warrants are exercised for cash (full cash exercise would yield approximately $29,929,998). Shares outstanding were 15,605,821 as of July 1, 2026.